Axa
OVID icon

Axa’s Ovid Therapeutics OVID Stock Holding History

Axa’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-620,402
Closed -$1.43M – 1303
2020
Q4 		$1.43M Buy
620,402
+25,735
+4% +$120K ﹤0.01% 916
2020
Q3 		$3.41M Sell
594,667
-115,283
-16% -$771K 0.01% 723
2020
Q2 		$5.23M Sell
709,950
-106,122
-13% -$496K 0.02% 602
2020
Q1 		$2.43M Sell
816,072
-51,530
-6% -$174K 0.01% 690
2019
Q4 		$3.6M Buy
+867,602
New +$2.74M 0.01% 706

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Axa's OVID Position: Q1 2021 in Review

Axa sold out of Ovid Therapeutics (OVID) in Q1 2021, closing a stake of 620,402 shares — an estimated $1.43M sold.

Axa first reported a position in OVID in Q4 2019 and held it in 5 quarters. The position peaked at $5.23M in Q2 2020. 88 funds tracked by Wall St. Rank hold OVID as of Q1 2021.

  • Axa reported no remaining Ovid Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Axa sold 620,402 Ovid Therapeutics shares in Q1 2021, an estimated $1.43M.
  • Axa first reported a position in Ovid Therapeutics in Q4 2019 and held it in 5 quarters.
  • Axa's Ovid Therapeutics position peaked at $5.23M in Q2 2020.
  • 88 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2021.

Based on Axa's 13F filing for Q1 2021, filed 14 May 2021.